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By using tissue microdissection and polymerase chain reaction (PCR) techniques, we examined 85 prostate tumors that were
paired with normal tissues from the same patients for allelic loss at 26 highly polymorphic microsatellite sequences, 21 spanning
8p and 5 localized to 8q. Sixty-four tumors (75%) demonstrated loss of at least one 8p locus. Separate distal and proximal
regions of deletion were observed as well as an intervening, staggered breakpoint. A novel region of homozygous deletion of
sequences at the D8S87 locus was detected both by multiplex PCR and by fluorescence in situ hybridization within this
breakpoint region. These data suggest that a tumor-suppressor gene mapping to proximal 8p is deleted frequently and is likely
to be important for tumorigenesis in prostate tumors. Genes Chromosomes Cancer 23:255–262,1998. r 1998 Wiley-Liss, Inc.
INTRODUCTION
It is likely that many genetic and epigenetic
events are involved in tumorigenesis. In particular,
recent cytogenetic and molecular studies have sug-
gested that deletion or rearrangement of sequences
that map to the short arm of chromosome 8 may be
permissive for tumorigenesis in several organ sys-
tems. In prostate carcinoma, early work by Berger-
heim et al. (1993) utilizing Southern blot tech-
niques observed high frequencies of deletion of
distal 8p sequences in human prostate tumors,
suggesting that a breakpoint existed between the
NEFL locus at 8p21 and the PLAT locus at 8p21–
8p11. Subsequent work by Bova et al. (1993) and
our laboratory (Wolman et al., 1992; Macoska et al.,
1993) identified a major region of deletion mapping
to 8p22 in human prostate cancer (PCa), which is
characterized by a homozygous deletion mapping
within the 8p22–p23 region in a prostate tumor
(Bova et al., 1996). The use of polymerase chain
reaction (PCR) and fluorescence in situ hybridiza-
tion (FISH) techniques in our laboratory and by
others confirmed frequent heterozygous loss of
distal 8p sequences (Macoska et al., 1994; MacGro-
gan et al., 1994; Sakr et al., 1994) and showed that
this region of deletion could be quite extensive,
including the entire 8p chromosome arm or large
portions of 8p extending from 8pter to 8p11–12
(MacGrogan et al., 1994; Trapman et al., 1994). We
later reported interstitial deletions of distal se-
quences mapping to 8p22 or 8p21 or proximal loci
mapping to 8p11–12 in human prostate tumors
(Macoska et al., 1995). Other laboratories reported
deletional domains encompassing or including 8p22
and 8p21-p12 (Vocke et al., 1996), interstitial losses
and homozygous deletions at 8p21 and 8p22 (Kagan
et al., 1995; Suzuki et al., 1995), interstitial losses of
two separate proximal deletional domains
(Crundwell et al., 1996), and isolation of a potential
tumor suppressor gene mapping to 8p21.3–p22
(Fujiwara et al., 1995). Recent studies have
also mapped a putative prostate metastasis sup-
pressor gene to the 8p21-p12 region (Nihei et al.,
1996).
Taken together, these studies suggest that there
are at least two large 8p sequence domains that are
deleted in prostate, bladder, and other cancers:
distal sequences encompassing 8pter-p21 (some-
times divided further into smaller, separate dele-
tional domains) and proximal sequences encompass-
ing 8p11–p12. In this report, we present data that
demonstrate frequent and sometimes homozygous
deletion of specific sequences mapping to proximal
8p. This information should facilitate the isolation
and cloning of one or more putative proximal 8p
tumor-suppressor genes that are inactivated in a
variety of human cancers.
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MATERIALS AND METHODS
Tissue Characterization
Prostate tissue was obtained after radical prosta-
tectomy from 85 patients diagnosed with PCa. After
an initial pathologic evaluation of radical prostatec-
tomy tissue, presumed malignant and normal tissue
was snap frozen in liquid nitrogen and stored at
270°C. Tumor specimens comprising areas of at
least 70% malignant cells and nontumor specimens
comprising normal or hyperplastic epithelium were
serially sectioned at 4 microns. One section was
stained with hematoxylin/eosin for histologic evalu-
ation, and discrete areas of benign or malignant
glands were then excised from adjacent nonstained
sections. DNA was extracted as described previ-
ously (Macoska et al., 1993, 1994, 1995; Sakr et al.,
1994). Serum prostate-specific antigen (PSA) val-
ues were obtained within a 1-week period prior to
surgery.
Analysis of DNA for Allelic Loss
PCR was utilized for amplification of 26 se-
quences containing highly polymorphic microsatel-
lite repeat markers at loci of interest on chromo-
some 8:21 loci that map to 8p and 5 that map to
proximal 8q. The linkage order of these markers





19-D8S1098-D8S538-D8S589-qter (where / indi-
cates markers of uncertain relative order; see Fig. 1).
Microsatellite-specific primer sequences mapping
near the WRN locus at the D8S1105 locus were as
reported (Ye et al., 1995). Cytogenetic localizations
were available for the following markers: 8pter-
p23.1, D8S549; 8p21, NEFL; 8p12, D8S87; and
8q11.2-q12, D8S1104 (as reported by the Human
Genome Data Base; GDB; http://gdbwww.gdb.org).
Primer sequences, additional linkage and contig
information, and genetic mapping information were
obtained from public databases maintained by the
GDB, the Center for Genome Research at the
Whitehead Institute for Biomedical Research (http://
www-genome.wi.mit.edu/), the Cooperative Hu-
man Linkage Center (CHLC; http://www.chl-
c.org/), and the National Center for Biotechnology
Information (http://www.ncbi.nlm.nih.gov/ ), as ac-
cessed through the Internet.
PCR reactions were performed as described pre-
viously (Trybus et al., 1996). Aliquots of each
reaction were electrophoresed on 6% acrylamide/7
M urea sequencing gels, and the gels were autora-
diographed. Allelic loss was scored when the ratio
of allelic signal intensities in tumor tissue was #
50% of that for the same alleles in normal tissue
from the same heterozygous patient by two indepen-
dent observers (M.A.P. or T.M.T. and J.A.M.).
Statistical analysis was performed by x2 test, with P
values , 0.05 considered statistically significant.
Instances of putative homozygous loss were inves-
tigated further by multiplex PCR analysis, in which
two primer sets were introduced simultaneously
into the same reaction mixtures. The failure to
produce an amplification product from one of the
two amplicons in a multiplex reaction was inter-
preted as homozygous loss of the sequence that
failed to amplify.
Fluorescence In Situ Hybridization
Slides were prepared from frozen tissues as
described previously (Macoska et al., 1994). A
clone, 303f13, mapping to the D8S87 locus was
isolated by PCR amplification of a microsatellite
marker specific for that region from a human BAC
DNA library (Research Genetics, Inc., Huntsville,
AL). Subsequent analysis confirmed that BAC
303f13 contains sequences specific for D8S87 (cyto-
genetically localized to 8p12) and WI-4330 (mapped
to chromosome 8) and produces no more than two
discrete fluorescent signals when it is labeled and
hybridized to cut sections of normal prostatic epithe-
lium (see Table 1). These findings are consistent
with an exclusive chromosome 8 localization for
this BAC. One microgram of BAC 303f13 was
labeled via nick translation with 20 µM fluorescein-
11-dUTP (FluoroGreen; Amersham, Buckingham-
shire, United Kingdom). Unincorporated nucleo-
tide was eliminated by passage through Sephadex
G-25. The labeled DNA was digested with EcoRI
and ethanol precipitated in the presence of Cot-1
(10 µg) DNA, yeast tRNA (25 µg), and sonicated
salmon testes DNA (25 µg). The probe was then
resuspended in 10 µl formamide and combined
with an equal volume of hybridization solution (to
final concentrations of 25% dextran sulfate, 2.5
µg/ml bovine serum albumin, 2.5 3 standard saline
citrate; SSC). One microliter of rhodamine-labeled
chromosome 8 pericentromeric probe DNA (CEP8
SpectrumOrange; Vysis, Downers Grove, IL) was
added to the hybridization mixture and applied to
the prepared slide, which was coverslipped and
sealed. The slide was incubated at 90°C for 10
minutes and was then incubated at 37°C overnight.
Unbound probe was removed by washing the slide
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Figure 1. Deletion profile of 64 prostate tumors with allelic loss of
8p sequences. Loci are shown at the top of the figure and are oriented
from 8pter on the left to 8cen on the right and refer to ‘‘D8’’
designations (with the exceptions of the NEFL and AFM295zd5 loci).
Prostate tumors are refered to by case number on the y-axis. Type
refers to major region of deletion, D (distal), P (proximal), or DP (distal
1 proximal). Allelic loss patterns are indicated as follows: R, both alleles
retained (white boxes); N, not informative (light gray boxes); and L, loss
of one allele (dark gray boxes). Extended light and dark gray shaded
areas show probable contiguous regions of deletion. The black box
designated ‘‘HL’’ shows a region of homozygous allelic loss. The extents
of the distal (black bar) and proximal (gray bar) regions of deletion are
indicated at the top, as is the breakpoint (black and gray hatched bar).
Allelic loss frequencies for individual loci (out of a total of 85 tumors) are
shown at the bottom. Specific cases discussed in the text are highlighted.
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in 2 3 SSC for 30 minutes each successively at
room temperature, at 37°C, and at 45°C, then at
70°C for 5 minutes. The slide was stored at 4°C in
1 3 phosphate-buffered detergent (0.1M Na2HPO4,
0.1M NaH2PO4, 0.5% NP-40) (PBD) prior to coun-
terstaining and visualization.
Nuclei were counterstained with DAPI/antifade,
and slides were visualized using a mercury light
source and appropriate filters (Chroma Optical,
Brattelboro, VT) on a photomicroscope (Zeiss Ax-
iophot, Thornwood, NY). The x,y coordinates of
microscope fields at 3 1,000 within areas of appro-
priate histology of normal and tumor tissues were
noted, and nuclei of 200 epithelial cells were
enumerated for the BAC and CEP8 probes. Careful
attention was given to counting only tissue areas of
appropriate histology with good nuclear morphol-
ogy. Two observers (M.A.P., J.A.M.) independently
counted each slide using the same x,y coordinates,
and the average of the two sets of counts was
determined. The values obtained from two observ-
ers typically agreed with each other within 10%.
RESULTS AND DISCUSSION
Frequent and Often Independent Deletion of Distal
and Proximal 8p Sequences
In an effort to define the 8p regions of deletion,
we utilized PCR techniques to determine the
allelic loss pattern of 26 highly polymorphic micro-
satellite sequences spanning 8p23-q12 for 85 paired
normal and malignant tissues from cancerous hu-
man prostates. This analysis revealed loss of hetero-
zygosity (LOH) of at least one 8p locus in 75% (64
of 85) of the tumors examined. This frequency is
consistent with that obtained by other studies using
more exacting or semiquantitative techniques, such
as tissue laser microdissection (Vocke et al., 1996),
phosphorimaging (MacGrogan et al., 1994), or fluo-
rescence in situ hybridization (FISH; Macoska et
al., 1994).
The deletion profiles of the 64 tumors with LOH
are shown in Figure 1. Insufficient tissue precluded
the complete analysis of six tumors (472, 129, 432,
476, 77, 484). Of the remaining 58 of 85 tumors,
four (2, 454, 482, 504) demonstrated LOH for all 8p
loci examined and were likely deleted for the entire
8p arm. An equivalent number of tumors (cases 23,
31, 322, and 488) were deleted for all 8p and 8q loci
examined and were apparently reduced to mono-
somy for chromosome 8. Thus, eight tumors demon-
strated substantial losses of chromosome 8 se-
quences. However, the majority of tumors examined
in this study were deleted for extended regions
rather than for all 8p sequences. Among the 64
cases with allelic loss, distal 8p sequences (8pter-
p21), including D8S549, D8S1715, D8S1116,
D8S1739, NEFL, D8S137, D8S1423, D8S540,
D8S1125, D8S259, and D8S513 (indicated as ‘‘D’’
in Fig. 1), were deleted in 23 (27%) of tumors
examined. Proximal 8p sequences (8p11-p12), in-
cluding D8S1105, D8S535, D8S505, D8S87,
D8S255, D8SD1118, D8S1121, and AFMA295zd5
(indicated as ‘‘P’’ in Fig. 1), were deleted in 16 cases
(25%). Both distal and proximal sequences (‘‘DP’’
in Fig. 1) were deleted contiguously in 25 cases
(39%). Thus, separate or independent deletion of
distal or proximal sequences (39 cases) was ob-
served more frequently than contiguous deletion of
both regions (25 cases) in these tumors. It should be
noted that, in six cases (119, 127, 500, 486, 498,
129), the most distal portion of an otherwise contigu-
ously deleted distal region was retained.
Identification of a Proximal 8p Breakpoint
A potential ‘‘breakpoint’’ may be identified from
the data shown above in Figure 1. The boundary of
this breakpoint appears somewhat ‘‘staggered’’ for
many tumors (compare the proximal boundary for
cases 498, 432, 224, and 242 with the distal bound-
ary for cases 416, 434, and 460), roughly between
D8S137 and D8S87. The maximal extent of this
breakpoint can be defined as inclusive of loci
D8S259, D8S513, D8S1105, D8S535, D8S505, and
D8S87, which are all tightly linked and map within
an approximately one megabase region between 64
cM and 65 cM on the genetic map (as reported by
the Center for Genome Research at the Whitehead
Institute for Biomedical Research). Although the
TABLE 1. Fluorescence In Situ Hybridization Analysis of Ho-








1,1 9 (5) 8 (4)
1,2 26 (13) 61 (30)
2,2 123 (62) 19 (10)
0,2 15 (7) 97 (49)
Other 27 (13) 15 (7)
Total (100) (100)
Total 8p loss 50 (25) 166 (83)
Case 512
1,1 10 (5) 2 (1)
1,2 48 (24) 46 (23)
2,2 108 (54) 108 (54)
0,2 18 (9) 27 (13)
Other 16 (8) 17 (9)
Total (100) (100)
Total 8p loss 76 (38) 75 (38)
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linkage order of these markers is uncertain, they are
presented here in the order most consistent with
the Whitehead Institute and with our deletion data.
To evaluate data from the current study in terms
of what has been reported previously, it is critical to
examine the definition of distal and proximal re-
gions of 8p deletion in these studies. For example,
several studies examined 8p loss using the marker
D8S259, which comprises a part of the distal border
of the 8p breakpoint defined in the present study.
Observation of allelic loss patterns near and includ-
ing D8S259 reported by MacGrogan et al. (1994)
shows that 8 of 14 ‘‘group II’’ prostate tumors were
deleted for 8p sequences immediately distal to or
inclusive of D8S259, although the marker order
D8S259-D8S137-D8S87 was used rather than the
D8S137-D8S259-D8S87 order used here. Also, a
few tumors were deleted separately for a region
proximal to D8S137 in that study (MacGrogan, et
al., 1994). Similarly, the study by Takle and Knowles
(1996) demonstrated two 8p regions of deletion in a
series of bladder carcinomas, one distal to and
another proximal to loci inclusive of D8S259, al-
though the marker order D8S505-D8S259-D8S513
was used rather than the D8S259-D8S513-D8S505
order used here. Inspection of their data also
suggests the presence of a staggered ‘‘breakpoint’’
overlapping the proximal region of deletion and
inclusive of loci D8S535, D8S505, D8S259, and
D8S513. Moreover, realignment of these markers to
conform with the order used in the current study
does not essentially change the interpreation of
their results.
A study by Trapman et al. (1994) demonstrated a
large region of contiguous distal 8p allelic loss
suggestive of a breakpoint proximal to nearby
D8S137 (which maps distal to D8S259) in 9 of 26
prostates with 8p loss. Similarly, Farrington et al.
(1996) defined one region of 8p loss distal to and
another proximal to D8S137 in a series of colorectal
carcinomas. A previous study from our laboratory
also defined two separate regions of deletion distal
to D8S137 as well as a third region of deletion
proximal to that marker (Macoska et al., 1995).
Vocke et al. (1996) described a major region of 8p
deletion distal to and inclusive of D8S137, although
it was more limited in extent than the major distal
regions of deletion described in the other studies
cited above.
Thus, it appears that all of these studies basically
agree with a finding of one or more distal regions of
8p loss extending proximal to D8S137/D8S259,
although they disagree on the presence of a sepa-
rate region of 8p loss proximal to these markers.
The basis of these discrepancies may be that 1)
these studies did not examine the allelic loss
pattern for markers mapping between D8S137/
D8S259 and D8S87; 2) the physical order of mark-
ers mapping between D8S137/D8S259 and D8S87
is ambiguous, making data interpretation difficult;
3) the number of tumors examined in some studies
may have been insufficient for the detection of
discrete regions of allelic loss; and 4) there were
probably differences in DNA preparation and gel
evaluation, because fractional allelic loss frequen-
cies range from 22% to 89% in these studies (MacGro-
gan et al., 1994; Trapman et al., 1994; Kagan et al.,
1995; Macoska et al., 1995; Takle and Knowles,
1996; Farrington et al., 1996; Vocke et al., 1996).
It is interesting that the putative proximal 8p
breakpoint identified here appears to be ‘‘stag-
gered,’’ in that it spans at least one megabase. Such
‘‘staggered’’ breakpoints have been observed for
other chromosomes, notably the X chromosome,
and have been implicated in the formation of
dicentric isochromosomes (Wolff et al., 1996). Loss
of 8p sequences apparently concurrent with 8q gain
has been observed in prostate tumors by using
FISH (Macoska et al., 1994) and comparative ge-
nomic hybridization (Visakorpi et al., 1995) tech-
niques, potentially resulting from iso(8q) chromo-
some formation (Jenkins et al., 1997). The deletion
data presented here are consistent with these sce-
narios.
Identification of a Homozygous Deletion
at the D8S87 Locus
One tumor from case 2 (see Fig. 1) failed
repeatedly to amplify at the D8S87 locus. To
determine whether this was due to homozygous
deletion at D8S87, we assayed paired normal and
tumor tissue from case 2 by using multiplex PCR
with primers to polymorphic sequences at D8S87
and primers to polymorphic sequences mapping
distal (D8S505, D8S535) or proximal (D8S255,
D8S1121) to D8S87. In all cases, DNA from case 2
tumor tissue failed to amplify at the D8S87 locus.
Multiplex reactions showing coamplification of se-
quences at D8S87 and D8S1121 are shown in
Figure 2 and show that two alleles that are 151 and
149 base pairs (bp) in length, respectively, amplify
from the D8S87 locus in normal tissues from cases 2
and 23. However, both alleles fail to amplify in
tumor tissue from case 2, and only the 149-bp allele
amplifies appreciably in tumor tissue from case 23,
suggestive of homozygous deletion (case 2) and
heterozygous deletion (case 23) of D8S87 se-
quences, respectively. Coamplification of trinucleo-
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tide repeat sequences at the D8S1121 locus reveals
equivalent amplification of alleles 121 bp and 118
bp in size in normal tissue from case 2 and of alleles
124 bp and 115 bp in size in normal tissue from case
23. However, the corresponding tumors demon-
strate heterozygous loss involving allele 121 in
tumor 2 and heterozygous loss involving allele 124
in tumor 23. Furthermore, PCR analysis of loci
producing amplicons larger than that of the D8S87
locus (e.g., the D8S549, D8S513, D8S505, D8S535,
and D8S538 loci) was successful (see Fig. 1),
suggesting that failure to amplify sequences from
the tumor from case 2 DNA at the D8S87 locus was
not due to DNA degradation. The ability to amplify
sequences from one chromosome 8 homologue at
the D8S1121 locus and the concurrent inability to
amplify sequences from either chromosome 8 homo-
logue at the D8S87 locus are consistent with the
presence of a small homozygous deletion including
the D8S87 locus in the tumor from case 2. This is
the first report of homozygous deletion in this
region of 8p in human tumors. Interestingly, the
tumor from case 2 did not demonstrate homozygous
loss at the D8S505 locus, which colocalizes to a 1.4
Mb CEPH yeast artifical chromosome, 898-G-11,
suggesting that the region of homozygous loss may
be less than 1.4 Mb in length.
To further verify the putative homozygous dele-
tion at D8S87 in tumor 2, we performed FISH
experiments. A human BAC clone, 303f13, contain-
ing sequences amplifiable at the D8S87 locus was
labeled via nick translation with fluorescein-
labeled dUTP (Amersham) and cohybridized with
a rhodamine-labeled chromosome 8 centeromere-
specific probe (Spectrum CEP8; Vysis) to the same
normal and tumor tissues from case 2 (with the
putative homozygous deletion at D8S87 by PCR
analysis) and case 512 (with no deletion at D8S87
by PCR analysis). Two hundred nuclei from each of
the four hybridized tissues were then enumerated
for the number of D8S87-specific (‘‘8p’’) and centro-
mere-specific (‘‘8c’’) probe signals (Table 1). Five
types of nuclei were scored: those with 8p,8c counts
equal to 1,1 (presumed monosomic for chromosome
8), 0,2 (presumed homozygous loss of 8p se-
quences), 1,2 (presumed heterozygous loss of 8p
sequences), 2,2 (presumed disomic, with retention
of 8p and 8c sequences), and other. Our data
demonstrated a loss of 83% of D8S87-specific
signal in the case 2 tumor compared with 25% in
the corresponding normal tissue section. In con-
trast, case 512 demonstrated a loss of 38% of
D8S87-specific signal in both normal and tumor
tissue sections (Table 1). These data are consistent
with the PCR data, suggesting complete or nearly
complete loss of D8S87-specific sequences in case
2, with retention of the same sequences in case 512.
The degree of apparent loss of D8S87-specific
sequences in the normal tissues of case 2 (20%) and
in both tissues from case 512 (33–36%) is consistent
with that obtained from sectioned tissue and is
likely to be due to ‘‘slice artifact,’’ as reported
previously (Wolman et al., 1993; .Macoska et al.,
1994; Jenkins et al., 1997).
Homozygous deletion has been interpreted in
other studies as indicating the physical localization
Figure 2. Homozgyous deletion at the D8S87 locus in a prostate
tumor. Autroradiograph of a gel showing the results of multiplex
polymerase chain reaction analysis using primers to the D8S87 and
D8S1121 loci in paired normal (N) and tumor (T) tissues from cases 2
and 23. Alleles that are 151 and 149 base pairs (bp) in length,
respectively, from the D8S87 locus amplify equivalently in normal tissues
from cases 2 and 23. However, both alleles fail to amplify in tumor tissue
from case 2, and only the 149-bp allele amplifies appreciably in tumor
tissue from case 23, suggesting a homozygous deletion (case 2) and a
heterozygous deletion (case 23) of D8S87 sequences, respectively.
Coamplification of trinucleotide repeat sequences at the D8S1121 locus
reveals equivalent amplification of 121-bp and 118-bp alleles in normal
tissue from case 2 and of 124-bp and 115-bp alleles in normal tissue from
case 23. However, the corresponding tumors demonstrate heterozy-
gous losses involving a 121-bp allele in the tumor from case 2 and a
124-bp allele in the tumor from case 23. The ability to amplify sequences
from one chromosome 8 homologue at the D8S1121 locus and the
concurrent inability to amplify sequences from either chromosome 8
homologue at the D8S87 locus are consistent with the presence of a
small homozygous deletion, including the D8S87 locus in the tumor
from case 2.
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of tumor-suppressor genes, and, most recently, it
aided in the molecular cloning of two such genes,
DPC-4 (Hahn et al., 1996) and PTEN (Li et al.,
1997). Therefore, evidence of homozygous loss of
the D8S87 locus in a human prostate tumor is
consistent with the hypothesis that a proximal 8p
tumor-suppressor gene is important in prostate
tumorigenesis and maps this tumor-suppressor gene
more precisely to a location at or near the D8S87
locus.
Correlation of 8p Deletional Regions with Clinical
and Pathological Parameters
The frequency of distal, distal1proximal, proxi-
mal, and lack of allelic loss was correlated with
tumor pathologic stage, combined Gleason score
(grade), preoperative serum PSA values, and age at
diagnosis of the PCa patients in this study group. A
breakdown of the number of tumors in each cat-
egory is provided in Table 2. There were no
statistically significant differences between the num-
ber of tumors in each of the four categories (distal,
distal 1 proximal, proximal, and lack of allelic loss)
in relation to pathologic stage (P 5 0.924), grade
(P 5 0.890), preoperative PSA (P 5 0.224), or age
at diagnosis (P 5 0.558). Because ethnic origin was
not recorded for 28 of 85 (33%) patients included in
this study, statistical evaluation of that variable was
not attempted.
CONCLUSIONS
In conclusion, this study identifies the physical
location of a proximal 8p breakpoint, and it demon-
strates a novel homozygous deletion of the proxi-
mal D8S87 locus in human prostate tumors. The
data are consistent with the hypothesis that a
proximal 8p tumor-suppressor gene that is impor-
tant for prostate tumorigenesis maps at or near the
D8S87 locus and should facilitate the isolation and
cloning of candidate tumor-suppressor genes from
this region.
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